152 related articles for article (PubMed ID: 24342395)
1. Is timing everything?
Rizzieri D
Biol Blood Marrow Transplant; 2014 Feb; 20(2):145-6. PubMed ID: 24342395
[No Abstract] [Full Text] [Related]
2. Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?
Ustun C; DeFor TE; Rashidi A; Devine S; Miller J; Weisdorf D
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1804-1808. PubMed ID: 28688918
[No Abstract] [Full Text] [Related]
3. CD34+ cell dose in allogeneic transplantation: weight considerations.
Basquiera AL; Abichaín P; Damonte JC; García JJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):196. PubMed ID: 25270957
[No Abstract] [Full Text] [Related]
4. Allogeneic Hematopoietic Cell Transplantation for AML-A Missed Opportunity!
O'Donnell MR
J Natl Compr Canc Netw; 2016 Sep; 14(9):1052-3. PubMed ID: 27587618
[No Abstract] [Full Text] [Related]
5. Sequential reduced-intensity chemotherapy for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia with rare cytogenetic abnormalities transformed from Fanconi anemia.
Inoue A; Mori A; Yamazaki S; Suzuki R; Takitani K; Tamai H
Pediatr Int; 2018 Sep; 60(9):893-894. PubMed ID: 30255979
[No Abstract] [Full Text] [Related]
6. Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.
Jones CV; Copelan EA
Future Oncol; 2009 May; 5(4):559-68. PubMed ID: 19450182
[TBL] [Abstract][Full Text] [Related]
7. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison.
Mohty M; de Lavallade H; El-Cheikh J; Ladaique P; Faucher C; Fürst S; Vey N; Coso D; Stoppa AM; Gastaut JA; Chabannon C; Blaise D
Leukemia; 2009 Jan; 23(1):194-6. PubMed ID: 18580956
[No Abstract] [Full Text] [Related]
8. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
Yilmaz M; Daver N; Borthakur G; Kadia T; DiNardo C; Kanagal-Shamanna R; Loghavi S; Oran B; Popat UR; Pierce S; Jabbour E; Short NJ; Issa G; Ohanian M; Konopleva M; Patel K; Kantarjian H; Ravandi F
Am J Hematol; 2021 Aug; 96(8):E275-E279. PubMed ID: 33891709
[No Abstract] [Full Text] [Related]
9. The role of allografting in adults with acute leukaemia.
Marks DI
Bone Marrow Transplant; 2008 Mar; 41(5):413-4. PubMed ID: 18334991
[No Abstract] [Full Text] [Related]
10. Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
Percival MM; Medeiros BC; Tian L; Robeson S; Laport GG; Johnston LJ; Shizuru JA; Miklos DB; Arai S; Weng WK; Negrin RS; Lowsky R
Bone Marrow Transplant; 2015 Jul; 50(7):1004-1006. PubMed ID: 25893457
[No Abstract] [Full Text] [Related]
11. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
Craddock CF
Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation.
Moukalled NM; El Darsa H; Haibe Y; Massoud R; Kanj SS; Mahfouz R; Bazarbachi A; El-Cheikh J
Bone Marrow Transplant; 2019 Apr; 54(4):620-624. PubMed ID: 30287936
[No Abstract] [Full Text] [Related]
13. Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy.
Khouri I; Giralt S; Champlin R
Cancer Treat Res; 2002; 110():137-47. PubMed ID: 11908196
[No Abstract] [Full Text] [Related]
14. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.
Jethava YS; Sica S; Savani B; Socola F; Jagasia M; Mohty M; Nagler A; Bacigalupo A
Bone Marrow Transplant; 2017 Nov; 52(11):1504-1511. PubMed ID: 28504666
[TBL] [Abstract][Full Text] [Related]
15. Choosing for whom to recommend allogeneic transplantation for acute myeloid leukemia in CR1: a continued, complicated conversation.
Menghrajani KN; Tallman MS
Blood Adv; 2018 Jan; 2(2):164. PubMed ID: 29365325
[No Abstract] [Full Text] [Related]
16. Allografting older patients--myths and realities.
Giralt S
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):146-8. PubMed ID: 19147096
[No Abstract] [Full Text] [Related]
17. Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy.
Gui G; Dillon LW; Hourigan CS
J Clin Oncol; 2021 Jul; 39(21):2413-2415. PubMed ID: 33950704
[No Abstract] [Full Text] [Related]
18. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
19. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.
Nazha A; Rybicki L; Abounader D; Bolwell B; Dean R; Gerds AT; Jagadeesh D; Hamilton BK; Hill BT; Kalaycio M; Liu H; Pohlman B; Sobecks R; Sekeres MA; Majhail NS
Bone Marrow Transplant; 2016 Dec; 51(12):1642-1643. PubMed ID: 27721371
[No Abstract] [Full Text] [Related]
20. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
